Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods: 2022-2025

Historic Finished Goods for Gyre Therapeutics (GYRE) over the last 2 years, with Sep 2025 value amounting to $3.3 million.

  • Gyre Therapeutics' Finished Goods rose 84.19% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 84.19%. This contributed to the annual value of $2.6 million for FY2024, which is 91.50% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Finished Goods is $3.3 million, which was down 3.57% from $3.4 million recorded in Q2 2025.
  • Gyre Therapeutics' Finished Goods' 5-year high stood at $3.4 million during Q2 2025, with a 5-year trough of $1.4 million in Q4 2023.
  • In the last 3 years, Gyre Therapeutics' Finished Goods had a median value of $2.2 million in 2024 and averaged $2.4 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Finished Goods decreased by 2.43% in 2023, and later surged by 122.77% in 2025.
  • Gyre Therapeutics' Finished Goods (Quarterly) stood at $1.4 million in 2022, then decreased by 2.43% to $1.4 million in 2023, then soared by 91.50% to $2.6 million in 2024, then surged by 84.19% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.4 million for Q2 2025, and $3.3 million during Q1 2025.